Evidence map›Paper›PMID 31354301›Full record

ArticleOncoTargets and therapy2019

Effects of BCc1 nanoparticle and its mixture with doxorubicin on survival of murine 4T1 tumor model.

Maryam Hafizi, Masoud Soleimani, Sajad Noorian, Somayeh Kalanaky, Saideh Fakharzadeh, Nafiseh Tavakolpoor Saleh, Mohammad Hassan Nazaran, Mohammad Esmaeil Akbari

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Maryam HafiziCancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Masoud SoleimaniDepartment of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Sajad NoorianDepartment of Statistics, Faculty of Sciences, University of Qom, Qom, Iran.
Somayeh KalanakyDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Saideh FakharzadehDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Nafiseh Tavakolpoor SalehStem Cell Technology Research Center, Tehran, Iran.
Mohammad Hassan Nazaran *Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Mohammad Esmaeil Akbari *Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahid Beheshti University of Medical Sciences · IRStem Cell Technology Research Center · IRTarbiat Modares University · IRUniversity of Qom · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BCc1 nanoparticlecancerdoxorubicinmurine 4T1 tumor modelnanochelating technology

Identifiers

PMID31354301
PMCPMC6590627
OpenAlexW2952760236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.